9 -8 (94) 2026 - Qodirova Sh.S., Nabieva D.A. - SURUNKALI YURAK YETISHMOVCHILIGI VA METABOLIK SINDROM BIRGA KECHGAN BEMORLARDA DAVOLASH NATIJALARI

SURUNKALI YURAK YETISHMOVCHILIGI VA METABOLIK SINDROM BIRGA KECHGAN BEMORLARDA DAVOLASH NATIJALARI

Qodirova Sh.S., Nabieva D.A. - Abu Ali ibn Sino nomidagi Bukhoro davlat tibbiyot instituti

Rezyume

Maqsad. Metabolik sindrom bilan birga kechgan surunkali yurak yetishmovchiligi (SYuYe) bo‘lgan bemorlarda standart va kompleks davolashning klinik-funksional, gemodinamik, metabolik hamda yallig‘lanish ko‘rsatkichlariga ta’sirini qiyosiy baholash. Material va usullar. 2022–2025-yillarda o‘tkazilgan prospektiv ochiq qiyosiy tadqiqotga 40–75 yoshdagi SYuYe va metabolik sindrom tashxisi qo‘yilgan 200 nafar bemor kiritildi. Bemorlar standart terapiya (n=100) va standart terapiyaga qo‘shimcha ravishda individual kardio-metabolik korreksiya olgan kompleks terapiya (n=100) guruhlariga ajratildi. Kuzatuv 12 oy davom etdi. Chap qorincha chiqarish fraksiyasi (ChQChF), E/e′, TAPSE, NT-proBNP, C-reaktiv oqsil (CRO), IL-6, glyukoza, HbA1c, HOMA-IR, lipid profili, 6 daqiqalik yurish testi (6DYuT), NYHA funksional sinfi va MLHFQ so‘rovnomasi baholandi. Natijalar. Guruhlar boshlang‘ich klinik-demografik ko‘rsatkichlar bo‘yicha o‘zaro taqqoslanadigan edi (p>0,05). Har ikkala guruhda ijobiy dinamika kuzatildi, biroq kompleks terapiya guruhida ChQChF va TAPSEning oshishi, E/e′, NT-proBNP, IL-6, CRO va HOMA-IRning kamayishi, 6DYuT masofasining uzayishi hamda hayot sifati yaxshilanishi yaqqolroq bo‘ldi (guruhlararo p<0,05). Metabolik va yallig‘lanish markerlaridagi o‘zgarishlar yurak yetishmovchiligining funksional holati bilan bog‘liq edi. Xulosa. SYuYe va metabolik sindrom birga kechgan bemorlarda yurak yetishmovchiligi bo‘yicha dalillarga asoslangan terapiyani metabolik xavf omillarini individual korreksiya qilish bilan birlashtirish klinik, funksional va laborator natijalarni yaxshilaydi.

Kalit so‘zlar: surunkali yurak yetishmovchiligi, metabolik sindrom, insulin rezistentligi, NT-proBNP, yallig‘lanish, kompleks terapiya.

First page

64

Last page

69

For citation:Qodirova Sh.S., Nabieva D.A. - SURUNKALI YURAK YETISHMOVCHILIGI VA METABOLIK SINDROM BIRGA KECHGAN BEMORLARDA DAVOLASH NATIJALARI//New Day in Medicine 8(94)2026 64-69 https://newdayworldmedicine.com/en/new_day_medicine/8-94-2026

ADABIYOTLAR RO’YXATI

  1. McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627-3639. doi:10.1093/eurheartj/ehad195.
  2. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063.
  3. Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention, National Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-1645. doi:10.1161/CIRCULATIONAHA.109.192644.
  4. Purwowiyoto SL, Prawara AS. Metabolic syndrome and heart failure: mechanism and management. Egypt Heart J. 2021;73(1):36. doi:10.1186/s43044-021-00154-3.
  5. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038.
  6. Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089-1098. doi:10.1056/NEJMoa2206286.
  7. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa1911303.
  8. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424. doi:10.1056/NEJMoa2022190.
  9. Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043-4140. doi:10.1093/eurheartj/ehad192.
  10. American Diabetes Association Professional Practice Committee. Cardiovascular disease and risk management: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S216-S245. doi:10.2337/dc26-S010.

    file

    download